Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC
NCT07777822 · RASolve 308 Phase 3Recruiting
- Lead sponsor
- Revolution Medicines, Inc. (Industry)
- Enrollment
- 430 (estimated)
- Start date
- 14 Aug 2026
- Primary completion
- Oct 2029 (estimated)
- Study completion
- 1 Feb 2031
- Last update posted
- 20 Aug 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Double
- Arms
- 2
Interventions
- zoldonrasib Drug
- Placebo Drug
- pembrolizumab Drug
- pemetrexed + cisplatin /carboplatin Drug
Conditions and primary outcome
- NSCLC
- Non-small Cell Lung Cancer
- Non-Small Cell Lung Cancer NSCLC
- Non-Squamous Non Small Cell Lung Cancer
- Lung Cancer (NSCLC)
- Metastatic NSCLC - Non-Small Cell Lung Cancer
- Metastatic Non-Squamous Non-Small Cell Lung Cancer
Primary outcome
Progression free survival (PFS) (Up to approximately 5 years)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07777822.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07777822 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.